Press release
Myotonic Dystrophy Market Size in the 7MM was ~USD 80 Million in 2023, estimated DelveInsight
Myotonic Dystrophy Market
Explore the intricate details of the Myotonic Dystrophy Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Myotonic Dystrophy Market Forecast. Click here to stay ahead in healthcare innovation @ Myotonic Dystrophy Market Size- https://www.delveinsight.com/sample-request/myotonic-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Myotonic Dystrophy Market Report
• Based on DelveInsight's assessment in 2023, the 7MM had 88,322 diagnosed prevalent cases of Myotonic Dystrophy, and it is projected that these cases will experience an increasing growth trend with an estimated CAGR during the forecast period (2024-2034).
• According to DelveInsight's analysis, in the US in 2023, diagnosed prevalent cases of Myotonic Dystrophy were reported as 2,625 for children (18 years).
• According to DelveInsight's estimates, among the type-specific diagnosed prevalent cases of Myotonic Dystrophy in the US, were more prevalent for DM1.
• The leading Myotonic Dystrophy Companies such as Lupin, AMO Pharma, Harmony Biosciences, Avidity Biosciences, Dyne Therapeutics, Nexien BioPharma, Locana, Inc., Entrada Therapeutics, Arthex Biotech, NeuBase Therapeutics, NeuBase Therapeutics, Enzerna, Enzerna, Astellas Gene Therapies, Dyne Therapeutics, Pepgen Corporation, Sangamo Therapeutics, Syros Pharmaceuticals, and others.
• Promising Myotonic Dystrophy Therapies such as Mexiletine, AOC 1001 (del-desiran), Tideglusib, ATX-01, VX-670, and others.
Navigate the complexities of the Myotonic Dystrophy Market: Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Myotonic Dystrophy Market Forecast. Click here to get more insights @ Myotonic Dystrophy Treatment Market- https://www.delveinsight.com/sample-request/myotonic-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Myotonic Dystrophy Epidemiology Segmentation in the 7MM
• Total Diagnosed Prevalent Cases
• Age-specific Diagnosed Prevalent Cases
• Type-specific Diagnosed Prevalent Cases
• Type-specific Diagnosed Prevalent Cases of DM1
• Comorbidity-associated Diagnosed Cases
Delve deep into the Myotonic Dystrophy Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Myotonic Dystrophy Market Forecast. Click here to shape the future @ Myotonic Dystrophy Prevalence- https://www.delveinsight.com/sample-request/myotonic-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Myotonic Dystrophy Market Insights
Myotonic Dystrophy is a rare, inherited disorder with multi-systemic effects that impact the skeletal muscles, eyes, heart, skin, gastrointestinal, endocrine, respiratory, and central nervous systems. Despite several pre-clinical developments, no specific disease-modifying therapy is currently available. Management consists primarily of monitoring for complications and standard of care (assistive devices, hormone therapy, and pain medication). A few clinical studies have systematically evaluated the use of therapeutic agents in DM. The lack of scientific evidence paired with the multi-systematic and highly variable presentation of the disease makes identifying and selecting appropriate medications particularly challenging for prescribing physicians.
Myotonic Dystrophy Drug Market
According to DelveInsight's' estimates, the Myotonic Dystrophy market in 7MM is expected to show positive growth, during the forecast period (2024-2034), mainly attributed to the anticipated launch of emerging therapies and the increasing cases of Myotonic Dystrophy. The Myotonic Dystrophy pipeline features several drugs in mid- to late-stage development poised for future approval. Anticipated launches of emerging therapies from companies like AMO Pharma Limited, Harmony Biosciences, Vertex Pharmaceuticals, among others, are expected to positively impact the market. Notably, EditForce, Inc. is advancing EF-210, a novel gene therapy program utilizing its proprietary PPR platform technology, targeting Myotonic Dystrophy Type 1 (DM1). EF-210 is currently undergoing preclinical development, promising innovative prospects in DM1 treatment with potential advancements in gene therapy approaches.
Unlock insights into the Myotonic Dystrophy Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Myotonic Dystrophy Market Forecast. Click here @ Myotonic Dystrophy Market Drivers and Barriers- https://www.delveinsight.com/sample-request/myotonic-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Myotonic Dystrophy Emerging Drugs
Myotonic Dystrophy drug developers are gradually shifting their attention toward Myotonic Dystrophy to meet the patient pool's current demands and counter the unmet needs of the therapeutic market. Several companies are working robustly on many new therapies, such as AMO-02 (AMO Pharma Limited), mexiletine (Lupin Ltd.), and pitolisant (Harmony Biosciences, LLC). AMO-02 (AMO Pharma Limited) is in development for treating congenital myotonic dystrophy (CDM) and has the potential for use in additional CNS, neuromuscular and other orphan indications. It has a dual mechanism disrupting the pathogenic RNA repeat in CDM1 and inhibiting excess levels of the kinase GSK3β. Currently, the company conducts two Phase II/III studies in children and adolescents with CDM.
Gain a strategic edge in the Myotonic Dystrophy Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Myotonic Dystrophy Market Forecast. Click here to lead in advancements @ Myotonic Dystrophy Clinical Trials Assessment- https://www.delveinsight.com/sample-request/myotonic-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Myotonic Dystrophy Market Report
• Coverage- 7MM
• Myotonic Dystrophy Companies- Lupin, AMO Pharma, Harmony Biosciences, Avidity Biosciences, Dyne Therapeutics, Nexien BioPharma, Locana, Inc., Entrada Therapeutics, Arthex Biotech, NeuBase Therapeutics, NeuBase Therapeutics, Enzerna, Enzerna, Astellas Gene Therapies, Dyne Therapeutics, Pepgen Corporation, Sangamo Therapeutics, Syros Pharmaceuticals, and others.
• Myotonic Dystrophy Therapies- Mexiletine, AOC 1001 (del-desiran), Tideglusib, ATX-01, VX-670, and others.
• Myotonic Dystrophy Market Dynamics: Myotonic Dystrophy Market drivers and Myotonic Dystrophy Market Barriers
• Myotonic Dystrophy Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Myotonic Dystrophy Unmet Needs, KOL's views, Analyst's views, Myotonic Dystrophy Market Access and Reimbursement
Discover the latest advancements in Myotonic Dystrophy Treatment by visiting our website. Stay informed about how we're transforming the future @ https://www.delveinsight.com/sample-request/myotonic-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Key Insights
2. Report Introduction
3. Myotonic Dystrophy Market Overview at a Glance
4. Executive Summary of Myotonic Dystrophy
5. Disease background and overview
6. Epidemiology and Patient Population
7. Patient Journey
8. Emerging Therapies
9. Other Assets
10. Myotonic Dystrophy (DM): 7MM Analysis
11. SWOT Analysis
12. KOL Views
13. Unmet Need
14. Market Access
15. Acronyms and Abbreviations
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight
List of Top Selling Market Research Reports in 2024
Attention Deficit Hyperactivity Disorder Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Atopic Dermatitis Market- https://www.delveinsight.com/report-store/atopic-dermatitis-market
Adult T-Cell Leukemia Market- https://www.delveinsight.com/report-store/adult-t-cell-leukemia-lymphoma-market
Blastomycosis Market- https://www.delveinsight.com/report-store/blastomycosis-market
Gastroesophageal Junction Adenocarcinoma Market- https://www.delveinsight.com/report-store/gastroesophageal-junction-adenocarcinoma-market
Mantle Cell Lymphoma Market- https://www.delveinsight.com/report-store/mantle-cell-lymphoma-market
Post Operative Pain Management Market- https://www.delveinsight.com/report-store/post-operative-pain-management-market
Postoperative Pain Market- https://www.delveinsight.com/report-store/postoperative-pain-market
Prostate Cancer Market- https://www.delveinsight.com/report-store/prostate-cancer-market-insight
Transmucosal Drug Delivery Devices Market- https://www.delveinsight.com/report-store/transmucosal-drug-delivery-devices-market
Trauma Fixation Devices Market- https://www.delveinsight.com/report-store/trauma-devices-market
Restless Legs Syndrome Market- https://www.delveinsight.com/report-store/restless-legs-syndrome-market
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Contact Us
Yash Bhardwaj
info@delveinsight.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myotonic Dystrophy Market Size in the 7MM was ~USD 80 Million in 2023, estimated DelveInsight here
News-ID: 3624651 • Views: …
More Releases from DelveInsight Business Research LLP
Pemphigus Vulgaris Market Size (7MM) is going to be ~USD 360 million in 2025, an …
(Albany, USA) DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Explore In-depth insights into the evolving Pemphigus Vulgaris Market. Download sample report @ https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Pemphigus Vulgaris Market Report
• Among the 7MM, the United…
Underactive Bladder Therapeutics Market Size in the 7MM is Expected to Grow Majo …
DelveInsight's "Underactive Bladder Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Underactive Bladder, historical and forecasted epidemiology as well as the Underactive Bladder market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Explore In-depth insights into the evolving Underactive Bladder Market. Download sample report @ https://www.delveinsight.com/sample-request/underactive-bladder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Underactive Bladder Market Report
• In 2023, the prevalent cases of LUTS…
The Peripheral Nerve Injury Market Size (7MM) was ~USD 2.4 Billion in 2023, it i …
(Albany, USA) DelveInsight's "Peripheral Nerve Injury Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Peripheral Nerve Injury, historical and forecasted epidemiology as well as the Peripheral Nerve Injury market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Explore In-depth insights into the evolving Peripheral Nerve Injury Market. Download sample report @ https://www.delveinsight.com/sample-request/peripheral-nerve-injuries-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Peripheral Nerve Injury…
Acute Lymphocytic Leukemia Market Size (7MM) is going to be ~USD 1,878 Million i …
(Albany, USA) DelveInsight's "Acute Lymphocytic Leukemia Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Acute Lymphocytic Leukemia, historical and forecasted epidemiology as well as the Acute Lymphocytic Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Explore In-depth insights into the evolving Acute Lymphocytic Leukemia Market. Download sample report @ https://www.delveinsight.com/sample-request/acute-lymphocytic-leukemia-all-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Acute Lymphocytic…
More Releases for Myotonic
Myotonic Dystrophy Market Detailed Industry Report Analysis 2025-2034
Introduction
Myotonic dystrophy (DM) is one of the most common forms of adult-onset muscular dystrophy, characterized by progressive muscle weakness, myotonia, cardiac issues, respiratory complications, and cognitive impairment. It is caused by genetic mutations-most often in the DMPK gene (DM1) or the CNBP gene (DM2)-leading to toxic RNA repeats that disrupt normal cellular function.
Despite being a rare neuromuscular disorder, myotonic dystrophy presents significant unmet needs, as there is currently no cure…
UK Myotonic Dystrophy Drug Market Segments |Latest Innovations & Demands
"Detailed Study of Myotonic Dystrophy Drug Market (2024-2032)
New Analysis Of Myotonic Dystrophy Drug Market overview, spend analysis, imports, segmentation, key players and opportunity analysis 2024-2032. The study also includes an in-depth competitive analysis of the key market players, along with their company profiles, key observations related to product and business offerings, recent developments, and key market strategies.
It also provides a snapshot of the country's economy and Industry outlook. It provides…
Myotonic Dystrophy Medication Market Business Growth, Trends, and Challenges by …
A New report from the WGR, titled Myotonic Dystrophy Medication Market Report 2024 Market Size, Trends, and Global Forecast 2024-2032, offers a thorough analysis of the market's changing trends, investment opportunities, and competitive landscape. By the end of 2032, the Myotonic Dystrophy Medication market trends will be valued at USD 1.1, per a WGR analysis. Furthermore, the report projects that the Myotonic Dystrophy Medication market trends will grow at a…
Myotonic Dystrophy Market Size, Epidemiology, Analysis & Trends 2023-2033
Myotonic Dystrophy Market Report Overview:
Report Attribute Details
Base Year 2022
Forecast Years …
Myotonic Dystrophy Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 …
DelveInsight's, "Myotonic Dystrophy Pipeline Insight, 2023," report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Myotonic Dystrophy pipeline landscape. It covers the Myotonic Dystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Myotonic Dystrophy Pipeline…
Emerging Trends in the 2022-2029 Myotonic Dystrophy Medication Market
Global Industrial aspects of Myotonic Dystrophy Medication Sales Market 2023-2029: The global Myotonic Dystrophy Medication Market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Myotonic Dystrophy Medication is estimated to increase from $ million in…
